NEW Clinical Trial for EGFR Exon 20 insertion mutation now open

The FURVENT Phase 3 trial is now enrolling newly diagnosed patients with non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations.

This study, available at four UK sites, offers a potential first-line treatment option with the drug furmonertinib. Click below for more details about eligibility and locations.